Bioelectronics Corp (BIEL)

[3331]

A Bankrate survey released today says 36% of US adults are working a side hustle (earning an average of $891/month), in addition to their regular job, in order to pay the bills. A Facebook poster laid out a business plan a few weeks ago on how Actipatch could capitalize on this demand and fill this market niche perfectly. Actipatch works for most pain indications, and most people give it a 5-star rating. The most common complaint is that it's "out of stock" when they try to repurchase.

The suggested business plan was backed with realistic numbers and the projected revenues were very impressive. It would fill the void from the KT "exclusive" US contract being revoked, and it could also immediately exploit the huge veterinary market. The new high strength model could also be sold as a "wellness" product until FDA approval is granted.